Literature DB >> 476006

Studies in desferrioxamine and ferrioxamine metabolism in normal and iron-loaded subjects.

M R Summers, A Jacobs, D Tudway, P Perera, C Ricketts.   

Abstract

Plasma concentrations of desferrioxamine and ferrioxamine were measured following bolus injections of desferrioxamine and during 24 h infusions of the drug. [59Fe]ferrioxamine clearance and urinary iron excretion were also measured. Higher plasma ferrioxamine concentrations were found in iron loaded subjects and higher desferrioxamine concentrations in subjects with normal ironloads. There is a correlation between the circulating concentration of ferrioxamine during an infusion and the 48 h urinary iron excretion. The data suggests that the amount of iron chelated in vivo is related to an increase in the size of an intermediate chelatable pool rather than the total amount of the iron load. The well-recognized delay in urinary iron excretion appears to be related to active tubular reabsorption of ferrioxamine.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 476006     DOI: 10.1111/j.1365-2141.1979.tb01167.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  22 in total

1.  Trophozoite elimination in a rat model of Pneumocystis carinii pneumonia by clinically achievable plasma deferoxamine concentrations.

Authors:  S Merali; K Chin; R W Grady; A B Clarkson
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

2.  Growth and development in thalassaemia major patients with severe bone lesions due to desferrioxamine.

Authors:  V De Sanctis; A Pinamonti; A Di Palma; M Sprocati; G Atti; M R Gamberini; C Vullo
Journal:  Eur J Pediatr       Date:  1996-05       Impact factor: 3.183

3.  Lipophilic siderophores of Mycobacterium tuberculosis prevent cardiac reperfusion injury.

Authors:  L D Horwitz; N A Sherman; Y Kong; A W Pike; J Gobin; P V Fennessey; M A Horwitz
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

Review 4.  Microbial siderophores and their potential applications: a review.

Authors:  Maumita Saha; Subhasis Sarkar; Biplab Sarkar; Bipin Kumar Sharma; Surajit Bhattacharjee; Prosun Tribedi
Journal:  Environ Sci Pollut Res Int       Date:  2015-03-12       Impact factor: 4.223

5.  Iron overload: pathogenesis and treatment with chelating agents.

Authors:  H Huebers
Journal:  Blut       Date:  1983-08

6.  Bp44mT: an orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy.

Authors:  Y Yu; Y Suryo Rahmanto; D R Richardson
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

7.  Pharmacokinetics and renal elimination of desferrioxamine and ferrioxamine in healthy subjects and patients with haemochromatosis.

Authors:  P Allain; Y Mauras; D Chaleil; P Simon; K S Ang; G Cam; L Le Mignon; M Simon
Journal:  Br J Clin Pharmacol       Date:  1987-08       Impact factor: 4.335

8.  Deferoxamine and eflornithine (DL-alpha-difluoromethylornithine) in a rat model of Pneumocystis carinii pneumonia.

Authors:  A B Clarkson; M Sarić; R W Grady
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

9.  Clinically achievable plasma deferoxamine concentrations are therapeutic in a rat model of Pneumocystis carinii pneumonia.

Authors:  S Merali; K Chin; L Del Angel; R W Grady; M Armstrong; A B Clarkson
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

10.  Intravenous and subcutaneous desferrioxamine therapy in children with severe iron overload.

Authors:  G E Janka; P Möhring; M Helmig; R J Haas; K Betke
Journal:  Eur J Pediatr       Date:  1981-11       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.